Refractory nodular lymphocyte predominant hodgkin lymphoma transformed to T-cell/histiocyte-rich B-cell lymphoma in an adolescent: Salvage therapy with allogeneic bone marrow transplantation

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 12, 2008, Pages 959-962

  Couronné, Lucile ^a   Schneider, Pascale ^a   Picquenot, Jean Michel ^b   Laberge, Sophie ^b   Bastard, Christian ^b   Vannier, Jean Pierre ^a  

^a HÔPITAL CHARLES NICOLLE   (France)

^b CENTRE HENRI BECQUEREL   (France)

Author keywords

Allogeneic bone marrow transplantation; Autologous bone marrow transplantation; Poppema lymphoma; T cell histiocyte rich B cell lymphoma

Indexed keywords

ASPARAGINASE; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B CELL LYMPHOMA; CANCER GROWTH; CANCER RELAPSE; CASE REPORT; CLINICAL FEATURE; DRUG MEGADOSE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MALE; NODULAR LYPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PRIORITY JOURNAL; T CELL HISTIOCYTE RICH B CELL LYMPHOMA; ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CELL TRANSFORMATION; DIFFERENTIAL DIAGNOSIS; HISTIOCYTE; IMMUNOPHENOTYPING; LYMPH NODE; PATHOLOGY; SALVAGE THERAPY; T CELL LYMPHOMA; TUMOR RECURRENCE;

ADOLESCENT; BONE MARROW TRANSPLANTATION; CELL TRANSFORMATION, NEOPLASTIC; DIAGNOSIS, DIFFERENTIAL; HISTIOCYTES; HODGKIN DISEASE; HUMANS; IMMUNOPHENOTYPING; LYMPH NODES; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MALE; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS;

EID: 59149085788     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31818a9564     Document Type: Article

References (18)

1. Boudova L, Torlakovic E, Delabie J, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood. 2003;102: 3753-3758.
2. Rudiger T, Gascoyne RD, Jaffe ES, et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma. Ann Oncol. 2002;13:44-51.
3. Patte C, Auperin A, Michon J, et al. Société Française d'Oncologie Pediatrique. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97: 3370-3379.
4. Abramson JS. T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management. Oncologist. 2006;11:384-392.
5. Fraga M, Sanchez-Verde L, Forteza J, et al. T-cell/histiocyte-rich large B-cell lymphoma is a disseminated aggressive neoplasm: differential diagnosis from Hodgkin's lymphoma. Histopathology. 2002; 41:216-229.
6. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol. 2000;13:193-207.
7. Fan Z, Natkunam Y, Bair E, et al. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol. 2003;27:1346-1356.
8. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346: 235-242.
9. Ferrara F, Viola A, Copia C, et al. Therapeutic results in patients with relapsed diffuse large B cell Non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation. Hematol Oncol. 2006;24:73-77.
10. Vose JM, Rizzo DJ, Tao-Wu J, et al. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant. 2004;10: 116-127.
11. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684-3688.
12. Aksentijevich I, Jones RJ, Ambinder RF, et al. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006;12:965-972.
13. Doocey RT, Toze CL, Connors JM, et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol. 2005;131: 223-230.
14. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. European Bone Marrow Transplantation (EBMT) Lymphoma Registry. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31: 667-678.
15. Freytes CO, Loberiza FR, Rizzo JD, et al. Lymphoma Working Committee of the International Bone Marrow Transplant Registry. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood. 2004;104: 3797-3803.
16. De Lima M, van Besien KW, Giralt SA, et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997;19:121-127.
17. Seropian S, Bahceci E, Cooper DL. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma. Bone Marrow Transplant. 2003;32:763-769.
18. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004;104:3865-3871.